GNA11 Q209L	Uveal Melanoma	GNA11 Q209L	Uveal Melanoma	IDE196 Sensitive: C3 – Early Trials IDE196 Sensitive : C3	IDE196 Sensitive: C3 – Early Trials IDE196 Sensitive : C3
GNAQ mutation	Uveal Melanoma	GNAQ mutation	Uveal Melanoma	AEB071 Sensitive: C3 – Early Trials AEB071 Sensitive : C3	AEB071 Sensitive: C3 – Early Trials AEB071 Sensitive : C3
GNA11 mutation	Uveal Melanoma	GNA11 mutation	Uveal Melanoma	AEB071 Sensitive: C3 – Early Trials AEB071 Sensitive : C3	AEB071 Sensitive: C3 – Early Trials AEB071 Sensitive : C3
PRKCH-SPTB fusion	Cutaneous Melanoma	PRKCH-SPTB fusion	Cutaneous Melanoma	IDE196 Sensitive: D – Preclinical IDE196 Sensitive : D	IDE196 Sensitive: D – Preclinical IDE196 Sensitive : D
PRKCH fusion	Cutaneous Melanoma	PRKCH fusion	Cutaneous Melanoma	IDE196 Sensitive: D – Preclinical IDE196 Sensitive : D	IDE196 Sensitive: D – Preclinical IDE196 Sensitive : D
PRKCH fusion	Colorectal Cancer	PRKCH fusion	Colorectal Cancer	IDE196 Resistant: D – Preclinical IDE196 Resistant : D	IDE196 Resistant: D – Preclinical IDE196 Resistant : D
PRKCH-SPTB fusion	Colorectal Cancer	PRKCH-SPTB fusion	Colorectal Cancer	IDE196 Sensitive: D – Preclinical IDE196 Sensitive : D	IDE196 Sensitive: D – Preclinical IDE196 Sensitive : D
PRKCH-VWA2 fusion	Colorectal Cancer	PRKCH-VWA2 fusion	Colorectal Cancer	IDE196 Sensitive: D – Preclinical IDE196 Sensitive : D	IDE196 Sensitive: D – Preclinical IDE196 Sensitive : D
HIF1A-PRKCH fusion	Colorectal Cancer	HIF1A-PRKCH fusion	Colorectal Cancer	IDE196 Sensitive: D – Preclinical IDE196 Sensitive : D	IDE196 Sensitive: D – Preclinical IDE196 Sensitive : D
HIF1A-PRKCH fusion	Cutaneous Melanoma	HIF1A-PRKCH fusion	Cutaneous Melanoma	IDE196 Resistant: D – Preclinical IDE196 Resistant : D	IDE196 Resistant: D – Preclinical IDE196 Resistant : D
PRKCH-VWA2 fusion	Cutaneous Melanoma	PRKCH-VWA2 fusion	Cutaneous Melanoma	IDE196 Sensitive: D – Preclinical IDE196 Sensitive : D	IDE196 Sensitive: D – Preclinical IDE196 Sensitive : D
NF1 470G>T	Glioblastoma	NF1 470G>T	Glioblastoma	RO-31-8220 Sensitive: D – Preclinical RO-31-8220 Sensitive : D	RO-31-8220 Sensitive: D – Preclinical RO-31-8220 Sensitive : D
NF1 2195G>T	Glioblastoma	NF1 2195G>T	Glioblastoma	RO-31-8220 Sensitive: D – Preclinical RO-31-8220 Sensitive : D	RO-31-8220 Sensitive: D – Preclinical RO-31-8220 Sensitive : D
GNAQ Q209L	Uveal Melanoma	GNAQ Q209L	Uveal Melanoma	AEB071 Sensitive: D – Preclinical AEB071 Sensitive : D	AEB071 Sensitive: D – Preclinical AEB071 Sensitive : D
FLT3 G697R	Acute Myelogenous Leukemia	FLT3 G697R	Acute Myelogenous Leukemia	K-252a Sensitive: D – Preclinical K-252a Sensitive : D	K-252a Sensitive: D – Preclinical K-252a Sensitive : D
GNA11 mutation	Uveal Melanoma	GNA11 mutation	Uveal Melanoma	AEB071 + AHT956 Sensitive: D – Preclinical AEB071 + AHT956 Sensitive : D	AEB071 + AHT956 Sensitive: D – Preclinical AEB071 + AHT956 Sensitive : D
GNAQ mutation	Uveal Melanoma	GNAQ mutation	Uveal Melanoma	AEB071 + AHT956 Sensitive: D – Preclinical AEB071 + AHT956 Sensitive : D	AEB071 + AHT956 Sensitive: D – Preclinical AEB071 + AHT956 Sensitive : D
GNAQ Q209P	Uveal Melanoma	GNAQ Q209P	Uveal Melanoma	AEB071 Sensitive: D – Preclinical AEB071 Sensitive : D	AEB071 Sensitive: D – Preclinical AEB071 Sensitive : D
GNAQ Q209L	Uveal Melanoma	GNAQ Q209L	Uveal Melanoma	binimetinib + AEB071 Sensitive: D – Preclinical binimetinib + AEB071 Sensitive : D	binimetinib + AEB071 Sensitive: D – Preclinical binimetinib + AEB071 Sensitive : D
GNAQ mutation	Uveal Melanoma	GNAQ mutation	Uveal Melanoma	AEB071 + CGM097 Sensitive: D – Preclinical AEB071 + CGM097 Sensitive : D	AEB071 + CGM097 Sensitive: D – Preclinical AEB071 + CGM097 Sensitive : D
GNA11 mutation	Uveal Melanoma	GNA11 mutation	Uveal Melanoma	binimetinib + AEB071 Sensitive: D – Preclinical binimetinib + AEB071 Sensitive : D	binimetinib + AEB071 Sensitive: D – Preclinical binimetinib + AEB071 Sensitive : D
GNAQ mutation	Uveal Melanoma	GNAQ mutation	Uveal Melanoma	everolimus + AEB071 Sensitive: D – Preclinical everolimus + AEB071 Sensitive : D	everolimus + AEB071 Sensitive: D – Preclinical everolimus + AEB071 Sensitive : D
GNAQ mutation	Uveal Melanoma	GNAQ mutation	Uveal Melanoma	binimetinib + AEB071 Sensitive: D – Preclinical binimetinib + AEB071 Sensitive : D	binimetinib + AEB071 Sensitive: D – Preclinical binimetinib + AEB071 Sensitive : D
GNA11 mutation	Uveal Melanoma	GNA11 mutation	Uveal Melanoma	AEB071 + CGM097 Sensitive: D – Preclinical AEB071 + CGM097 Sensitive : D	AEB071 + CGM097 Sensitive: D – Preclinical AEB071 + CGM097 Sensitive : D
GNA11 mutation	Uveal Melanoma	GNA11 mutation	Uveal Melanoma	everolimus + AEB071 Sensitive: D – Preclinical everolimus + AEB071 Sensitive : D	everolimus + AEB071 Sensitive: D – Preclinical everolimus + AEB071 Sensitive : D
GNA11 mutation	Uveal Melanoma	GNA11 mutation	Uveal Melanoma	PD-0325901 + AEB071 Sensitive: D – Preclinical PD-0325901 + AEB071 Sensitive : D	PD-0325901 + AEB071 Sensitive: D – Preclinical PD-0325901 + AEB071 Sensitive : D
GNAQ mutation	Uveal Melanoma	GNAQ mutation	Uveal Melanoma	PD-0325901 + AEB071 Sensitive: D – Preclinical PD-0325901 + AEB071 Sensitive : D	PD-0325901 + AEB071 Sensitive: D – Preclinical PD-0325901 + AEB071 Sensitive : D
ER positive	HER2 Positive Breast Cancer	ER positive	HER2 Positive Breast Cancer	AEB071 Sensitive: D – Preclinical AEB071 Sensitive : D	AEB071 Sensitive: D – Preclinical AEB071 Sensitive : D
ER positive	Estrogen Receptor Positive Breast Cancer	ER positive	Estrogen Receptor Positive Breast Cancer	AEB071 Sensitive: D – Preclinical AEB071 Sensitive : D	AEB071 Sensitive: D – Preclinical AEB071 Sensitive : D

PKC inhibitor

PKC inhibitor

Associations(29)

Associations
(29)